Form 4: Olema Pharmaceuticals Director Ian Clark Receives Stock Option Grant

Olema Pharmaceuticals, Inc. Director Ian T. Clark was granted 24,150 stock options with an exercise price of $4.08, vesting over 12 months or until the next annual meeting.

Summary

• Ian T. Clark, a Director of Olema Pharmaceuticals, Inc. (OLMA), was granted stock options.
• The transaction date for the option grant was June 11, 2025.
• A total of 24,150 stock options were acquired.
• The exercise price for these options is $4.08 per share.
• The options become exercisable starting June 11, 2025, and expire on June 11, 2035.
• The shares subject to the option vest in 12 successive equal monthly installments from June 11, 2025, contingent on continuous service.
• Full vesting will occur on the date of the Issuer's next annual meeting of stockholders if not already fully vested, also subject to continuous service.
• Following this transaction, Mr. Clark beneficially owns 24,150 derivative securities directly.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a positive signal of continued alignment between management and shareholder interests, providing an incentive for long-term performance. It is a routine compensation event, not indicative of significant positive or negative news beyond that.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term performance.
• The vesting schedule encourages the director's continued service to the company.

Negatives

• The options are not immediately exercisable for all shares, as they are subject to a vesting schedule.
• The value of the options is dependent on the future stock price exceeding the exercise price of $4.08.

Risks

• The value of the stock options is subject to market fluctuations; if the company's stock price does not rise above the exercise price, the options may expire worthless.
• The vesting is contingent on continuous service, meaning the director must remain with the company to realize the full benefit.

Future Outlook

The document details a standard equity compensation grant to a director, with future vesting contingent on continued service and company performance, aligning the director's long-term incentives with shareholder value.

Industry Context

This Form 4 filing represents a routine insider transaction, specifically an equity grant to a director, which is a common practice in the biotechnology and pharmaceutical industry to attract and retain talent and align management incentives with long-term company performance.

Related Party Transactions

• The grant of stock options to Ian T. Clark, a Director of Olema Pharmaceuticals, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: Potential for minor future dilution upon exercise of options, but also increased alignment of director's interests with shareholder value creation.
• Management: The grant provides a long-term incentive for the director.

Next Steps

• The stock options will vest in 12 successive equal monthly installments from June 11, 2025.
• The options will fully vest on the date of the Issuer's next annual meeting of stockholders if not already fully vested by that date.
• The director must maintain continuous service to the company for the options to vest.

Key Dates

Keywords

Olema Pharmaceuticals, OLMA, Ian T Clark, Stock Options, SEC Form 4, Insider Transaction, Director Compensation, Equity Grant, Vesting Schedule